Working Group on a New Grand Bargain for Antimicrobial Procurement
June 27, 2022
While there have been high-level commitments from the World Health Assembly, the United Nations General Assembly (UNGA), the G20, and the G7 to tackle AMR, there has yet to be a fundamental change in how we purchase antimicrobials, or an international approach to improving access, fostering innovati...
Incorporating Economics and Modelling in Global Health Goals and Guidelines
November 15, 2017
International organizations influence national-level health sector priorities by affecting how much funding is available for healthcare delivery within countries and setting limits on how that funding is used. They exert particular influence in setting disease-specific targets, developing clinical g...
The Unintended Consequences of Rich Countries’ Anti–Money Laundering Policies on Poor Countries
January 23, 2015
The Unintended Consequences of Rich Countries’ Anti-Money Laundering Policies on Poor Countries Working Group examined how rich countries might rebalance their policies to continue to protect against money laundering and terrorism financing without hindering the ability of people from poor countries...
Drug Resistance Working Group (November 2007 – June 2010)
September 10, 2014
Value for Money: An Agenda for Global Health Funding Agencies
August 25, 2014
As international commitments become more ambitious and aid resources become increasingly constrained, global health funding agencies are seeking to improve the efficiency and impact of their investments. This growing “value for money” (VfM) agenda aims to reduce costs, increase imp...